Targeting the MET gene for the treatment of non-small-cell lung cancer

Critical Reviews in Oncology/Hematology

Volumn 89, Issue 2, 2014, Pages 284-299

  Gelsomino, F ^a   Facchinetti, F ^b   Haspinger, E R ^a   Garassino, M C ^a   Trusolino, L ^c   De Braud, F ^a   Tiseo, M ^b  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b UNIVERSITY HOSPITAL OF PARMA   (Italy)

^c UNIVERSITY OF TURIN   (Italy)

Author keywords

Hepatocyte growth factor; Kinase inhibitors; MET; NSCLC; Targeted therapies

Indexed keywords

BEVACIZUMAB; CABOZANTINIB; CRIZOTINIB; EPIDERMAL GROWTH FACTOR RECEPTOR 3; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; FICLATUZUMAB; FORETINIB; GEFITINIB; ONARTUZUMAB; PHOSPHATIDYLINOSITOL 3 KINASE; PLACEBO; PROTEIN KINASE B; RILOTUMUMAB; SCATTER FACTOR; SCATTER FACTOR RECEPTOR; TIVANTINIB;

ANTINEOPLASTIC ACTIVITY; CANCER GROWTH; CANCER PROGNOSIS; CANCER RESISTANCE; CARCINOGENESIS; CONSTIPATION; DIARRHEA; DISEASE ASSOCIATION; DRUG METABOLISM; DRUG RESISTANCE; DRUG TOLERANCE; ESOPHAGUS CANCER; FATIGUE; GENE AMPLIFICATION; GENE DOSAGE; GENE OVEREXPRESSION; GENE TARGETING; HAND FOOT SYNDROME; HEMATURIA; HUMAN; HYPERTENSION; HYPOXIA; LUNG NON SMALL CELL CANCER; MOLECULARLY TARGETED THERAPY; NAUSEA; ONCOGENE MET; OVERALL SURVIVAL; PERIPHERAL EDEMA; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POINT MUTATION; PROGRESSION FREE SURVIVAL; PROTEIN BINDING; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN STRUCTURE; PROTEINURIA; PROTO ONCOGENE; RASH; RECEPTOR BINDING; REVIEW; SIGNAL TRANSDUCTION; STOMACH CANCER; TRANSACTIVATION; TREATMENT DURATION; TREATMENT RESPONSE; TUMOR GROWTH; TUMOR INVASION; UBIQUITINATION; VOMITING;

ADVERSE EVENTS; AES; ALK; ANAPLASTIC LYMPHOMA KINASE; EGFR; EPIDERMAL GROWTH FACTOR RECEPTOR; FISH; FLUORESCENT IN SITU HYBRIDIZATION; HAZARD RATIO; HEPATOCYTE GROWTH FACTOR; HEPATOCYTE GROWTH FACTOR RECEPTOR; HGF; HGFR; HR; IHC; IMMUNOHISTOCHEMISTRY; INTENT TO TREAT; ITT; KINASE INHIBITORS; MAXIMUM TOLERATED DOSE; MET; MTD; NON SMALL CELL LUNG CANCER; NSCLC; OS; OVERALL SURVIVAL; PFS; PLEXIN-SEMAPHORIN-INTEGRIN; PROGRESSION FREE SURVIVAL; PSI; RTKS; SCLC; SEMA; SEMAPHORIN; SMALL CELL LUNG CANCER; TARGETED THERAPIES; TYROSINE KINASE RECEPTORS;

ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; DRUG RESISTANCE, NEOPLASM; HUMANS; LUNG; LUNG NEOPLASMS; MOLECULAR TARGETED THERAPY; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-MET; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 84892507836     PISSN: 10408428     EISSN: 18790461     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2013.11.006     Document Type: Review

References (142)

1. Lynch T.J., Bell D.W., Sordella R., et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004, 350:2129-2139.
2. Paez J.G., Janne P.A., Lee J.C., et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004, 304:1497-1500.
3. Sequist L.V., Bell D.W., Lynch T.J., Haber DA: Molecular predictors of response to epidermal growth factor receptor antagonists in non-small-cell lung cancer. J Clin Oncol 2007, 25:587-595.
4. Kwak E.L., Bang Y.J., Camidge D.R., et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 2010, 363:1693-1703.
5. Shaw A.T., Yeap B.Y., Solomon B.J., et al. Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis. Lancet Oncol 2011, 12:1004-1012.
6. Camidge D.R., Bang Y.J., Kwak E.L., et al. Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study. Lancet Oncol 2012, 13:1011-1019.
7. Shaw AT: Phase III study of crizotinib versus pemetrexed or docetaxel chemotherapy in patients with advanced ALK-positive NSCLC (PROFILE 1007). Proceedings of ESMO congress: 28 September-02 October Vienna 2012, [Abstract 2862].
8. Kim D.-W., Ahn M.-J., Shi Y., et al. Results of a global phase II study with crizotinib in advanced ALK-positive non-small cell lung cancer (NSCLC). J Clin Oncol 2012, 30:s7533.
9. Giordano S., Ponzetto C., Di Renzo M.F., Cooper C.S., Comoglio PM: Tyrosine kinase receptor indistinguishable from the c-met protein. Nature 1989, 339:155-156.
10. Prat M., Narsimhan R.P., Crepaldi T., Nicotra M.R., Natali P.G., Comoglio PM: The receptor encoded by the human c-MET oncogene is expressed in hepatocytes, epithelial cells and solid tumors. Int J Cancer 1991, 49:323-328.
11. Shattuck D.L., Miller J.K., Carraway K.L., Sweeney C. Met receptor contributes to trastuzumab resistance of Her2-overexpressing breast cancer cells. Cancer Res 2008, 68:1471-1477.
12. Siegfried J.M., Weissfeld L.A., Singh-Kaw P., Weyant R.J., Testa J.R., Landreneau RJ: Association of immunoreactive hepatocyte growth factor with poor survival in resectable non-small cell lung cancer. Cancer Res 1997, 57:433-439.
13. Sawada K., Radjabi A.R., Shinomiya N., et al. c-Met overexpression is a prognostic factor in ovarian cancer and an effective target for inhibition of peritoneal dissemination and invasion. Cancer Res 2007, 67:1670-1679.
14. Lo Muzio L., Farina A., Rubini C., et al. Effect of c-Met expression on survival in head and neck squamous cell carcinoma. Tumor Biol 2006, 27:115-121.
15. Ponzetto C., Bardelli A., Zhen Z., et al. A multifunctional docking site mediates signaling and transformation by the hepatocyte growth factor/scatter factor receptor family. Cell 1994, 77:261-271.
16. Furge K.A., Zhang Y.W., Vande Woude G.F. Met receptor tyrosine kinase: enhanced signaling through adapter proteins. Oncogene 2000, 19:5582-5589.
17. Pelicci G., Giordano S., Zhen Z., et al. The motogenic and mitogenic responses to HGF are amplified by the Shc adaptor protein. Oncogene 1995, 10:1631-1638.
18. Boccaccio C., Ando M., Tamagnone L., et al. Induction of epithelial tubules by growth factor HGF depends on the STAT pathway. Nature 1998, 391:285-288.
19. Zhang Y.W., Wang L.M., Jove R., Vande Woude G.F. Requirement of Stat3 signaling for HGF/SF-Met mediated tumorigenesis. Oncogene 2002, 21:217-226.
20. Sonnenberg E., Meyer D., Weidner K.M., Birchmeier C: Scatter factor/hepatocyte growth factor and its receptor, the c-met tyrosine kinase, can mediate a signal exchange between mesenchyme and ephitelia during mouse development. J Cell Biol 1993, 123:223-235.
21. Gherardi E., Sandin S., Petoukhov M.V., et al. Structural basis of hepatocyte growth factor/scatter factor and MET signalling. Proc Natl Acad Sci U S A 2006, 103:4046-4051.
22. Stamos J., Lazarus R.A., Yao X., Kirchhofer D., Wiesmann C: Crystal structure of the HGF beta-chain in complex with the sema domain of the Met receptor. EMBO J 2004, 23:2325-2335.
23. Johnson G.L., Lapadat R: Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases. Science 2002, 298:1911-1912.
24. Fan S., Gao M., Meng Q., et al. Role of NF-kappaB signaling in hepatocyte growth factor/scatter factor-mediated cell protection. Oncogene 2005, 24:1749-1766.
25. Muller M., Morotti A., Ponzetto C: Activation of NF-kappaB is essential for hepatocyte growth factor-mediated proliferation and tubulogenesis. Mol Cell Biol 2002, 22:1060-1072.
26. Guo A., Villen J., Kornhauser J., et al. Signaling networks assembled by oncogenic EGFR and c-MET. Proc Natl Acad Sci U S A 2008, 105:692-697.
27. Long I.S., Han K., Li M., et al. Met receptor overexpression and oncogenic Ki-ras mutation cooperate to enhance tumorigenicity of colon cancer cells in vivo. Mol Cancer Res 2003, 1:393-401.
28. Matsubara D., Ishikawa S., Oguni S., Aburatani H., Fukayama M., Niki T. Molecular predictors of sensitivity to the MET inhibitor PHA665752 in lung carcinoma cells. J Thorac Oncol 2010, 5:1317-1324.
29. Yang Y., Wislez M., Fujimoto N., et al. A selective small molecule inhibitor of c-Met, PHA-665752, reverses lung premalignancy induced by mutant K-ras. Mol Cancer Ther 2008, 7:952-960.
30. Pennacchietti S., Michieli P., Galluzzo M., Mazzone M., Giordano S., Comoglio P.M. Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene. Cancer Cell 2003, 3:347-361.
31. Conrotto P., Corso S., Gamberini S., Comoglio P.M., Giordano S. Interplay between scatter factor receptors and B plexins controls invasive growth. Oncogene 2004, 23:5131-5137.
32. Capparuccia L., Tamagnone L. Semaphorin signaling in cancer cells and in cells of the tumor microenvironment-two sides of a coin. J Cell Sci 2009, 122:1723-1736.
33. Kermorgant S., Parker P.J. c-Met signalling: spatio-temporal decisions. Cell Cycle 2005, 4:352-355.
34. Kermorgant S., Zicha D., Parker PJ: PKC controls HGF-dependent c-Met traffic, signalling and cell migration. EMBO J 2004, 23:3721-3734.
35. Kermorgant S., Parker P.J. Receptor trafficking controls weak signal delivery: a strategy used by c-Met for STAT3 nuclear accumulation. J Cell Biol 2008, 182:855-863.
36. Sorkin A., von Zastrow M. Endocytosis and signalling: intertwining molecular networks. Nat Rev Mol Cell Biol 2009, 10:609-622.
37. Hammond D.E., Urbe S., Vande Woude G.F., Clague M.J. Down-regulation of MET, the receptor for hepatocyte growth factor. Oncogene 2001, 20:2761-2770.
38. Foveau B., Ancot F., Leroy C., et al. Down-regulation of the met receptor tyrosine kinase by presenilin-dependent regulated intramembrane proteolysis. Mol Biol Cell 2009, 20:2495-2507.
39. Nath D., Williamson N.J., Jarvis R., Murphy G. Shedding of c-Met is regulated by crosstalk between a G-protein coupled receptor and the EGF receptor and is mediated by a TIMP-3 sensitive metalloproteinase. J Cell Sci 2001, 114:1213-1220.
40. Michieli P., Mazzone M., Basilico C., et al. Targeting the tumor and its microenvironment by a dual-function decoy Met receptor. Cancer Cell 2004, 6:61-73.
41. Bladt F., Riethmacher D., Isenmann S., Aguzzi A., Birchmeier C. Essential role for the c-met receptor in the migration of myogenic precursor cells into the limb bud. Nature 1995, 376:768-771.
42. Streit A., Stern C.D., Thery C., et al. A role for HGF/SF in neural induction and its expression in Hensen's node during gastrulation. Development 1995, 121:813-824.
43. Andermarcher E., Surani M.A., Gherardi E. Co-expression of the HGF/SF and c-met genes during early mouse embryogenesis precedes reciprocal expression in adjacent tissues during organogenesis. Dev Genet 1996, 18:254-266.
44. Gentile A., Trusolino C., Comoglio P.M. The Met tyrosine kinase receptor in development and cancer. Cancer Metastasis Rev 2008, 27:85-94.
45. Takayama H., La Rochelle W.J., Anver M., Bockman D.E., Merlino G. Scatter factor/hepatocyte growth factor as a regulator of skeletal muscle and neural crest development. Proc Natl Acad Sci U S A 1996, 93:5866-5871.
46. Bussolino F., Di Renzo M.F., Ziche M., et al. Hepatocyte growth factor is a potent angiogenic factor which stimulates endothelial cell motility and growth. J Cell Biol 1992, 119:629-641.
47. Birchmeier C., Gherardi E. Developmental roles of HGF/SF and its receptor, the c-Met tyrosine kinase. Trends Cell Biol 1998, 8:404-410.
48. Schmidt C., Bladt F., Goedecke S., et al. Scatter factor/hepatocyte growth factor is essential for liver development. Nature 1995, 373:699-702.
49. Uehara Y., Minowa O., Mori C., et al. Placental defect and embryonic lethality in mice lacking hepatocyte growth factor/scatter factor. Nature 1995, 373:702-705.
50. Huh C.G., Factor V.M., Sanchez A., Uchida K., Conner E.A., Thorgeirsson S.S. Hepatocyte growth factor/c-met signaling pathway is required for efficient liver regeneration and repair. Proc Natl Acad Sci USA 2004, 101:4477-4482.
51. Boccaccio C., Comoglio P.M. Invasive growth: a MET-driven genetic programme for cancer and stem cells. Nat Rev Cancer 2006, 6:637-645.
52. Danilkovitch-Miagkova A., Zbar B. Dysregulation of Met receptor tyrosine kinase activity in invasive tumors. J Clin Invest 2002, 109:863-867.
53. Feng Y., Thiagarajan P.S., Ma P.C. MET signaling: novel targeted inhibition and its clinical development in lung cancer. J Thorac Oncol 2012, 7:459-467.
54. Olivero M., Rizzo M., Madeddu R., et al. Overexpression and activation of hepatocyte growth factor/scatter factor in human non-small-cell lung carcinomas. Br J Cancer 1996, 74:1862-1868.
55. Maulik G., Kijima T., Ma P.C., et al. Modulation of the c-Met/hepatocyte growth factor pathway in small cell lung cancer. Clin Cancer Res 2002, 8:620-627.
56. Ma P.C., Tretiakova M.S., MacKinnon A.C., et al. Expression and mutational analysis of MET in human solid cancers. Genes Chromosomes Cancer 2008, 47:1025-1037.
57. Cappuzzo F., Marchetti A., Skokan M., et al. Increased MET gene copy number negatively affects survival of surgically resected non-small-cell lung cancer patients. J Clin Oncol 2009, 27:1667-1674.
58. Okuda K., Sasaki H., Yukiue H., Yano M., Fujii Y. MET gene copy number predicts the prognosis for completely resected non-small cell lung cancer. Cancer Sci 2008, 99:2280-2285.
59. Beau-Faller M., Ruppert A.M., Voegeli A.C., et al. MET gene copy number in non-small cell lung cancer: molecular analysis in a targeted tyrosine kinase inhibitor naïve cohort. J Thorac Oncol 2008, 3:331-339.
60. Park S., Choi Y.L., Sung C.O., et al. High MET copy number and MET overexpression: poor outcome in non-small cell lung cancer patients. Histol Histopathol 2012, 27:197-207.
61. Ichimura E., Maeshima A., Nakajima T., Nakamura T. Expression of c-met/HGF receptor in human non-small cell lung carcinomas in vitro and in vivo and its prognostic significance. Jpn J Cancer Res 1996, 87:1063-1069.
62. Takanami I., Tanana F., Hashizume T., et al. Hepatocyte growth factor and c-Met/hepatocyte growth factor receptor in pulmonary adenocarcinomas: an evaluation of their expression as prognostic markers. Oncology 1996, 53:392-397.
63. Masuya D., Huang C., Liu D., et al. The tumor-stromal interaction between intratumoral c-Met and stromal hepatocyte growth factor associated with tumor growth and prognosis in non-small-cell lung cancer patients. Br J Cancer 2004, 90:1555-1562.
64. Gumustekin M., Kargi A., Bulut G., et al. HGF/c-Met overexpression, but not Met mutation, correlates with progression of non-small cell lung cancer. Pathol Oncol Res 2012, 18:209-218.
65. Smolen G.A., Sordella R., Muir B., et al. Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752. Proc Natl Acad Sci U S A 2006, 103:2316-2321.
66. Baykal C., Demirtas E., Al A., et al. Comparison of hepatocyte growth factor levels of epithelial ovarian cancer cyst fluids with benign ovarian cysts. Int J Gynecol Cancer 2004, 14:152-156.
67. Tuck A.B., Park M., Sterns E.E., Boag A., Elliott BE: Coexpression of hepatocyte growth factor and receptor (Met) in human breast carcinoma. Am J Pathol 1996, 148:225-232.
68. Koochekpour S., Jeffers M., Rulong S., et al. Met and hepatocyte growth factor/scatter factor expression in human gliomas. Cancer Res 1997, 57:5391-5398.
69. Li G., Schaider H., Satyamoorthy K., Hanakawa Y., Hashimoto K., Herlyn M. Downregulation of E-cadherin and Desmoglein 1 by autocrine hepatocyte growth factor during melanoma development. Oncogene 2001, 20:8125-8135.
70. Ferracini R., Di Renzo M.F., Scotlandi K., et al. The Met/HGF receptor is over-expressed in human osteosarcomas and is activated by either a paracrine or an autocrine circuit. Oncogene 1995, 10:739-749.
71. Boon E.M., van der Neut R., van de Wetering M., Clevers H., Pals S.T. Wnt signaling regulates expression of the receptor tyrosine kinase met in colorectal cancer. Cancer Res 2002, 62:5126-5128.
72. Relaix F., Rocancourt D., Mansouri A., Buckingham M. Divergent functions of murine Pax3 and Pax7 in limb muscle development. Genes Dev 2004, 18:1088-1105.
73. Kanteti R., Nallasura V., Loganathan S., et al. PAX5 is expressed in small-cell lung cancer and positively regulates c-Met transcription. Lab Invest 2009, 89:301-314.
74. Ivan M., Bond J.A., Prat M., Comoglio P.M., Wynford-Thomas D. Activated ras and ret oncogenes induce over-expression of c-met (hepatocyte growth factor receptor) in human thyroid epithelial cells. Oncogene 1997, 14:2417-2423.
75. Shirasaki F., Makhluf H.A., LeRoy C., Watson D.K., Trojanowska M: Ets transcription factors cooperate with Sp1 to activate the human tenascin-C promoter. Oncogene 1999, 18:7755-7764.
76. Gambarotta G., Boccaccio C., Giordano S., Ando M., Stella M.C., Comoglio P.M. Ets up-regulates MET transcription. Oncogene 1996, 13:1911-1917.
77. Krishnaswamy S., Kanteti R., Duke-Cohan J.S., et al. Ethnic differences and functional analysis of MET mutations in lung cancer. Clin Cancer Res 2009, 15:5714-5723.
78. Yun C., Lee J.H., Park H., et al. Chemotherapeutic drug, adriamycin, restores the function of p53 protein in hepatitis B virus X (HBx) protein-expressing liver cells. Oncogene 2000, 19:5163-5172.
79. Zaffaroni D., Spinola M., Galvan A., et al. Met proto-oncogene juxtamembrane rare variations in mouse and humans: differential effects of Arg and Cys alleles on mouse lung tumorigenesis. Oncogene 2005, 24:1084-1090.
80. Jagadeeswaran R., Surawska H., Krishnaswamy S., et al. Paxillin is a target for somatic mutations in lung cancer: implications for cell growth and invasion. Cancer Res 2008, 68:132-142.
81. Ma P.C., Kijima T., Maulik G., et al. c-MET mutational analysis in small cell lung cancer: novel juxtamembrane domain mutations regulating cytoskeletal functions. Cancer Res 2003, 63:6272-6281.
82. Peschard P., Fournier T.M., Lamorte L., et al. Mutation of the c-Cbl TKB domain binding site on the Met receptor tyrosine kinase converts it into a transforming protein. Mol Cell 2001, 8:995-1004.
83. Ma P.C., Jagadeeswaran R., Jagadeesh S., et al. Functional expression and mutations of c-Met and its therapeutic inhibition with SU11274 and small interfering RNA in non-small cell lung cancer. Cancer Res 2005, 65:1479-1488.
84. Schmidt L., Duh F.M., Chen F., et al. Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. Nat Genet 1997, 16:68-73.
85. Cortesina G., Rosso P., Mola P., et al. Molecular markers study in pTNM of squamous carcinoma of the head and neck. Acta Otorhinolaryngol Ital 2000, 20:380-382.
86. Walz C., Sattler M. Novel targeted therapies to overcome imatinib mesylate resistance in chronic myeloid leukemia (CML). Crit Rev Oncol Hematol 2006, 57:145-164.
87. Engelman J.A., Janne P.A. Mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. Clin Cancer Res 2008, 14:2895-2899.
88. Engelman J.A., Zejnullahu K., Mitsudomi T., et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007, 316:1039-1043.
89. Bean J., Brennan C., Shih J.Y., et al. MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc Natl Acad Sci U S A 2007, 104:20932-20937.
90. Arteaga C.L. HER3 and mutant EGFR meet MET. Nat Med 2007, 13:675-677.
91. Arcila M.E., Oxnard G.R., Nafa K., et al. Rebiopsy of lung cancer patients with acquired resistance to EGFR inhibitors and enhanced detection of the T790M mutation using a locked nucleic acid-based assay. Clin Cancer Res 2011, 17:1169-1180.
92. Sequist L.V., Waltman B.A., Dias-Santagata D., et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med 2011, 3(75):ra26.
93. Turke A.B., Zejnullahu K., Wu Y.L., et al. Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC. Cancer Cell 2010, 17:77-88.
94. Cappuzzo F., Janne P.A., Skokan M., et al. MET increased gene copy number and primary resistance to gefitinib therapy in non-small-cell lung cancer patients. Ann Oncol 2009, 20:298-304.
95. Xu L., Kikuchi E., Xu C., et al. Combined EGFR/MET or EGFR/HSP90 inhibition is effective in the treatment of lung cancers codriven by mutant EGFR containing T790M and MET. Cancer Res 2012, 72:3302-3311.
96. Wang W., Li Q., Takeuchi S., et al. Met kinase inhibitor E7050 reverses three different mechanisms of hepatocyte growth factor-induced tyrosine kinase inhibitor resistance in EGFR mutant lung cancer. Clin Cancer Res 2012, 18:1663-1671.
97. Yano S., Yamada T., Takeuchi S., et al. Hepatocyte growth factor expression in EGFR mutant lung cancer with intrinsic and acquired resistance to tyrosine kinase inhibitors in a Japanese cohort. J Thorac Oncol 2011, 6:2011-2017.
98. Daniele G., Ranson M., Blanco-Codesido M., et al. Phase I dose-finding study of golvatinib (E7050), a c-Met and Eph receptor targeted multi-kinase inhibitor, administered orally QD to patients with advanced solid tumors. J Clin Oncol 2012, 30. [suppl; abstr 3030].
99. Alvarez R.H., Kantarjian H.M., Cortes J.E. The role of Src in solid and hematologic malignancies: development of new-generation Src inhibitors. Cancer 2006, 107:1918-1929.
100. Qi J., McTigue M.A., Rogers A., et al. Multiple mutations and bypass mechanisms can contribute to development of acquired resistance to MET inhibitors. Cancer Res 2011, 71:1081-1091.
101. Diamond J.R., Salgia R., Varella-Garcia M., et al. Initial clinical sensitivity and acquired resistance to MET inhibition in MET-mutated papillary renal cell carcinoma. J Clin Oncol 2013, 31:e254-e258.
102. Jun H.T., Sun J., Rex K., et al. AMG 102, a fully human anti-hepatocyte growth factor/scatter factor neutralizing antibody, enhances the efficacy of temozolomide or docetaxel in U-87 MG cells and xenografts. Clin Cancer Res 2007, 13:6735-6742.
103. Gordon M.S., Sweeney C.S., Mendelson D.S., et al. Safety, pharmacokinetics, and pharmacodynamics of AMG 102, a fully human hepatocyte growth factor neutralizing monoclonal antibody, in a first-in-human study of patients with advanced solid tumors. Clin Cancer Res 2010, 16:699-710.
104. Rosen P.J., Sweeney C.J., Park D.J., et al. A phase Ib study of AMG 102 in combination with bevacizumab or motesanib in patients with advanced solid tumors. Clin Cancer Res 2010, 16:2677-2687.
105. Oliner K.S., Tang R., Anderson A., et al. Evaluation of MET pathway biomarkers in a phase II study of rilotumumab (R AMG 102) or placebo (P) in combination with epirubicin, cisplatin, and capecitabine (ECX) in patients (pts) with locally advanced or metastatic gastric (G) or esophagogastric junction (EGJ) cancer. J Clin Oncol 2012, 30. [suppl; abstr 4005].
106. Patnaik A., Weiss G.J., Papadopoulos K., et al. Phase I study of SCH900105 (SC), an anti-hepatocyte growth factor (HGF) monoclonal antibody (MAb), as a single agent and in combination with erlotinib (E) in patients (pts) with advanced solid tumors. J Clin Oncol 2010, 28. [suppl; abstr 2525].
107. Tan E., Park K., Lim W.T., et al. Phase Ib study of ficlatuzumab (formerly AV-299), an anti-hepatocyte growth factor (HGF) monoclonal antibody (MAb) in combination with gefitinib (G) in Asian patients (pts) with NSCLC. J Clin Oncol 2011, 29. [suppl; abstr 7571].
108. Martens T., Schmidt N.O., Eckerich C., et al. A novel one-armed anti-c-Met antibody inhibits glioblastoma growth in vivo. Clin Cancer Res 2006, 12:6144-6152.
109. Jin H., Yang R., Zheng Z., et al. MetMab, the one-armed 5D5 anti-c-Met antibody, inhibits orthotopic pancreatic tumor growth and improves survival. Cancer Res 2008, 68:4360-4368.
110. Moss R.A., Patel P., Bothos J. Complete results from phase I dose escalation study of MetMab, a monovalent antagonist antibody to the receptor MET, doses as single agent and in combination with bevacizumab in patients with advanced solid malignancies. Ann Oncol 2010, 21(viii 165. Suppl. 8). abstract 504P.
111. Spigel D.R., Ervin T.J., Ramlau R., et al. Final efficacy results from OAM4558g, a randomized phase II study evaluating MetMAb or placebo in combination with erlotinib in advanced NSCLC. J Clin Oncol 2011, 29. [suppl: Abstr 7505].
112. Catenacci D.V., Henderson L., Xiao S.Y., et al. Durable complete response of metastatic gastric cancer with anti-Met therapy followed by resistance at recurrence. Cancer Discov 2011, 1:573-579.
113. Spigel D.R., Edelman M.J., Mok T., et al. Treatment rationale study design for the MetLung trial: a randomized, double-blind phase III study of onartuzumab (MetMab) in combination with erlotinib versus erlotinib alone in patients who have received standard chemotherapy for stage IIIB or IV Met-positive non-small-cell lung cancer. Clin Lung Cancer 2012, 13:500-504.
114. Blumenschein G.R., Mills G.B., Gonzales-Angulo A.M. Targeting the hepatocyte growth factor - cMet axis in cancer therapy. J Clin Oncol 2012, 30:3287-3290.
115. Bladt F., Faden B., Friese-Hamim M., et al. EMD 1214063 and EMD 1204831 constitute a new class of potent and highly selective c-Met inhibitors. Clin Cancer Res 2013, 19:2941-2951.
116. Munshi N., Jeay S., Li Y., et al. ARQ 197, a novel and selective inhibitor of the human c-Met receptor tyrosine kinase with antitumor activity. Mol Cancer Ther 2010, 9:1544-1550.
117. Basilico C., Pennacchietti S., Vigna E., et al. Tivantinib (ARQ197) displays cytotoxic activity that is independent of its ability to bind MET. Clin Cancer Res 2013, 19:2381-2390.
118. Katayama R., Aoyama A., Yamori T., et al. Cytotoxic activity of tivantinib (ARQ 197) is not due solely to c-MET inhibition. Clin Cancer Res 2013, 73:3087-3090.
119. Goldman J.W., Laux I., Chai F., et al. Phase 1 dose-escalation trial evaluating the combination of the selective MET inhibitor tivantinib (ARQ 197) plus erlotinib. Cancer 2012, 118:5903-5910.
120. Rosen L.S., Senzer N., Mekhail T., et al. A phase I dose-escalation study of tivantinib (ARQ 197) in adult patients with metastatic solid tumors. Clin Cancer Res 2011, 17:7754-7760.
121. Yap T.A., Olmos D., Brunetto A.T., et al. Phase I trial of a selective c-MET inhibitor ARQ 197 incorporating proof of mechanism pharmacodynamic studies. J Clin Oncol 2011, 29:1271-1279.
122. Sequist L.V., von Pawel J., Garmey E.G., et al. Randomized phase II study of erlotinib plus tivantinib versus erlotinib plus placebo in previously treated non-small-cell lung cancer. J Clin Oncol 2011, 29:3307-3315.
123. Scagliotti G.V., Novello S., Ramlau R., et al. Results of the phase 3 MARQUEE study: MET Inhibitor Tivantinib (ARQ 197) Plus Erlotinib vs Erlotinib Plus Placebo in NSCLC. Proceedings of 17th ECCO-38th ESMO-32nd ESTRO European cancer congress: 27 September-01 October 2013, [abstract E17-1821].
124. Nishina T., Hirashima T., Sugio K., et al. The effect of CYP2C19 polymorphism on the tolerability of ARQ 197, results from phase I trial in Japanese patients with metastatic solid tumors. J Clin Oncol 2011, 29. [suppl: abstr 2516].
125. Yakes F.M., Chen J., Tan J., et al. Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis and tumor growth. Mol Cancer Ther 2011, 10:2298-2308.
126. Wakelee H.A., Gettinger S.N., Engelman J.A., et al. A phase Ib/II study of XL184 (BMS 907351) with and without erlotinib (E) in patients (pts) with non-small cell lung cancer (NSCLC). J Clin Oncol 2010, 28. [15S: abstr 3017].
127. Gordon M.S., Vogelzang N.J., Schoffski P., et al. Activity of cabozantinib (XL184) in soft tissue and bone: results of a phase II randomized discontinuation trial (RDT) in patients (pts) with advanced solid tumors. J Clin Oncol 2011, 29. [suppl: abstr 3010].
128. Buckanovich R.J., Berger R., Sella A., et al. Activity of cabozantinib (XL184) in advanced ovarian cancer patients (pts): results from a phase II randomized discontinuation trial (RDT). J Clin Oncol 2011, 29. [suppl: abstr 5008].
129. Hussain M., Smith M.R., Sweeney C., et al. Cabozantinib (XL184) in metastatic castration-resistant prostate cancer (mCRPC): results from a phase II randomized discontinuation trial. J Clin Oncol 2011, 29. [suppl: abstr 4516].
130. Qian F., Engst S., Yamaguchi K., et al. Inhibition of tumor cell growth, invasion and metastasis by EXEL-2880 (XL880, GSK1363089), a novel inhibitor of HGF and VEGF receptor tyrosine kinases. Cancer Res 2009, 69:8009-8016.
131. Eder J.P., Shapiro G.I., Appleman L.J., et al. A phase I study of foretinib, a multi target inhibitor of c-MET and vascular endothelial growth factor receptor 2. Clin Cancer Res 2010, 16:3507-3510.
132. Choueiri T.K., Vaishampayan U., Rosenberg J.E., et al. Phase II and biomarker study of the dual MET/VEGFR inhibitor foretinib in patients with papillary renal cell carcinoma. J Clin Oncol 2013, 31:181-186.
133. Zou H.Y., Li Q., Lee J.H., et al. An orally available small molecule inhibitor of c-Met (PF-02341066) exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms. Cancer Res 2007, 67:4408-4417.
134. Cui J.J., Tran-Dubé M., Shen H., et al. Structure based drug design of crizotinib (PF-02341066), a potent and selective dual inhibitor of mesenchymal-epithelial transition factor (c-Met) kinase and anaplastic lymphoma kinase (ALK). J Med Chem 2011, 54:6342-6363.
135. Kwak E.L., Camidge D.R., Clark J., et al. Clinical activity observed in a phase I dose escalation trial of an oral c-met and ALK inhibitor. J Clin Oncol 2009, 27:3509. [suppl: abstr].
136. Ou S.H., Kwak E.L., Siwak-Tapp C., et al. Activity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplification. J Thorac Oncol 2011, 6:942-946.
137. Lennerz J.K., Kwak E.L., Ackerman A., et al. MET amplification identifies a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib. J Clin Oncol 2011, 29:4803-4810.
138. Chi A., Kwak E., Clark J., et al. Clinical improvement and rapid radiographic regression induced by a MET inhibitor in a patient with MET amplified glioblastoma. J Clin Oncol 2011, 29:2072. [suppl: abstr].
139. Tanizaki J., Okamoto I., Okamoto K., et al. MET tyrosine kinase inhibitor crizotinib (PF-02341066) shows differential antitumor effects in non-small cell lung cancer according to MET alterations. J Thorac Oncol 2011, 6:1624-1631.
140. Zhang Y., Farenholtz K., Yang Y., et al. Hepatocyte growth factor sensitizes brain tumors to c-Met kinase inhibition. Clin Cancer Res 2013, 19:1433-1440.
141. Infante J.R., Rugg T., Gordon M., et al. Unexpected renal toxicity associated with SGX523, a small molecule inhibitor of MET. Invest New Drugs 2013, 31:363-369.
142. Diaz D., Ford K.A., Hartley D.P., et al. Pharmacokinetic drivers of toxicity for basic molecules: Strategy to lower pKa results in decreased tissue exposure and toxicity for a small molecule Met inhibitor. Toxicol Appl Pharmacol 2013, 266:86-94.